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DR. WILLIAM H. ELLETT (Office of Radiation
Programs, U.S. EPA): I would like to begin with
Dr. Denniston's work in genetics. Something that
did not come out too clearly is that once we can
put some kind ofa range on the mutational effect
and relate it to heritability, only then can we
start to get some feeling for what is happening.
Now, we do know something about heritability.
We can study it by studying cousin marriages and
how mutations are propagated through cousin
marriages. There are good data on this subject in
England, Ireland, and to some extent, in this
country. One of the conclusions from looking at
heritability of different genetic diseases is that
they show up rarely, as Dr. Denniston pointed
out. That means we maybe talking about up to 40
generations for full expression of the genetic ef-
fect ofa radiation exposure. It occurred to me that
not Charlemagne but Charlemagne's parents
would now be seeing in their progeny the expres-
sion ofgenetic effects from background radiation.
It takes a very long time. Perhaps these things
should be discounted because they are so far in
the future, as Dr. Denniston suggested. My prob-
lem with that is that means we have to have the
perspective ofa Victorian optimist that there will
always be increased progress and particularly
increased medical progress, to overcome these
long-delayed effects. It may happen that medical
progress may plateau out, particularly as we find
we have to devote more and more ofour medical
resources to an aging population.
Thrning to what we have learned from Dr.
Upton and Dr. Radford, about the other so-called
stochastic effects ofradiation; this is mainly can-
cer, but perhaps some of the in utero effeets are
also stochastic. Whathave we learned aboutwhat
the kinetics ofthe radiation risk response? There
is certainly room for a wide range ofbeliefs about
the shape ofthe dose-response curve and I think
you saw some of this diversity expressed today.
We know that for many, ifnot all, ofthese effects,
it is unlikely there is a threshold dose. You will
never be able to prove the absence ofa threshold,
because at whatever dose you have data, I can
always suggest athreshold dose halfas large. But
we are starting now to see significant effects at
doses comparable to the doses that are received in
relatively brief spans of time, such as a year, by
radiation workers.
Also, we know that for all stochastic effects, as
the dose increases the likelihood of damage in-
crease, at least until cell-killing reducesthe popu-
lation ofcells at risk. This was shown very nicely
in Dr. Upton's presentation, and Dr. Radford also
referred to it. What we know is that at low levels
(and they are quite low-some data we have are
at 10 rad), effects increase with dose, in a more or
less linear fashion. Then for many systems-not
all but for many systems-there is apparently a
change in slopes, so that effects increase more
than linearity would predict. Experiments have
been done with quite small statistical errors on
this, so the change in slope is real.
Myproblem is I feel we shouldbe very careful if
we say this changed slope corresponds to a dose-
squared response. Sometimes, the slope is actu-
ally 2, but, on the other hand, for the same test
system but by using a different clone or different
conditions in the system, this slope can vary.
There are good data that show the response at
high doses has a slope as low as 1.2, others 1.4, or
1.8. A slope of 2 means that the effect is propor-
tional to the dose square, which can be related to
mathematical model of the dose-effect relation-
ship. When we have a dose-squared response, we
are inclined to invoke a two-hit model as was
pointed out by Dr. Upton. The problem is: when
we have a slope of 1.4, does that mean we have a
response for halfofan interaction? That's impos-
sible. I think there is more to this increased
response at high dose thanjust the physics. There
is some evidence that-what is happening is that
the repair system is being damaged and that is
why we are seeing more damage expressed at
high doses. The nonlinearity isn't from the phys-
ics ofthe situation, but rather from the biology.
I like physical or biophysical models because
they give us a theory to test, and that is some-
thingwe have beenlacking inbiology. But Ithink
we can carry them too far into our thinking,
particularly when we start carrying them into
the risk assessment area. Tirning to Dr. Rad-
ford's paper I would like to point out that fromDISCUSSION: SESSION II
what Dr. Radford said ontheJapanese data, there
is also room for skepticism. People have argued
for years on what the cancer data from Japan and
Nagasaki meant. The BEIR III report depends
very heavily on the Nagasaki data, almost to the
exclusion of everything else. To normalize the
Nagasaki data Hiroshima data were used, and
the Hiroshima data looked statistically pretty
good. No one looked at the denominator of the
risk coefficient, cases per rad. When we are talk-
ing about carcinogens at this conference, we are
talking about excess risk per unit dose ofone kind
or another. Just because the dose is measured in
physical units doesn't mean that we have a very
good estimate of it. A lot ofpeople feel that they
have been burned by the Japanese data and we
did not know the true component ofneutron dose.
My own feeling is we all forgot to be skeptical
scientists. Because doses were printed and used
by everyone in 1965, we accepted the T-65 doses
as not having much uncertainty. We were clearly
wrong in that. I would like to urge caution as the
next generation of dose estimates comes along; I
am sure there will be better dose estimates but
there will still be room for skepticism. There is
also room for skepticism in the Japanese cancer
data until we have full lifetime follow-up. That
may not occur in my lifetime. We do not yet know
the full extent ofthe disease. It may change and
we will see quite different slopes as we follow
these data further.
Finally, I would like to talk about Eric Hall's
work, which was shown to us by Dr. Upton, where
we saw an increased frequency ofcell transmuta-
tions for fractionated irradiation and for chronic
irradiation compared to single acute doses. Such
results are completely to the contrary ofwhat we
thought might be true. The National Council on
Radiation Protection has recommended that
agencies that protect the public health assign (for
low dose rate, low-LET radiation) less risk then
was observed in Japan and other places which
had high doses over a short period of time. They
state that the risks that are estimated on the
basis ofacute dose results might be 2 to 10 times
smaller at lower dose rates. When I look at Eric
Hall's data, I wonder ifthis is good advice. Would
the panel comment on the implications of Hall's
results? And the second thing I would like the
panel to discuss is, what is the best approach for
deriving risks from epidemiological data? Risk
estimates can be arrived at by a wide variety of
mathematical functions. BEIR III took the ap-
proach that you should not use the simplest func-
tion that fits the data which is linear, but rather a
function that had a basis in radiobiology theory.
DR. UPrON (N.Y. Univ. School of Medicine):
Appropos ofDr. Ellett's point, what do we make of
this anomalous enhancing effect on the transfor-
mation of C3H x 10-T-1/2 mouse embryo cells in
culture that is observed when a dose ofa 100 rads,
let's say, is delivered in two exposures separated
by 5-hr intervals or protracted over a period of 5
to 6 hr? That result flies in the face of the other
experience we have had with other carefully eval-
uated systems. What sort ofred flag does it send
up? How do we react to it?
I think my own reaction would be one ofwatch-
ful waiting. The transformation ofcells in culture
is so dependent on many variables that until this
observation is replicated in several different labo-
ratories and we have a better understanding ofit,
I don't think we should use it as a basis for risk
estimates for radiological protection in humans. I
would attach greater weight to in vivo studies, in
animals and in human populations where we
have them, and the classical systems that have
been thoroughly investigated the world over,
chromosome aberration induction and mutagene-
sis. At the same time, I think it does emphasize
the gaps in our knowledge. I would support Dr.
Ellett in his contention that the models we put on
the board, these equations, allow us to fit func-
tions to the data with a high degree ofagreement
frequently. Butthere are exceptions in the models
that do not adequately take into account the
complexity ofthe biological systems we are work-
ing with. So that I would not, as I said at the
outset, take the enhancing effectthat I referred to
initially as something we can predict will happen
in vivo, but we can't be sure that it will not
happen and wejust have to watch that phenome-
non as it is studied and resolved in the laboratory.
DR. RADFORD (University of Pittsburgh): I
would like to respond to a number of the points
that were made both by Dr. Ellett and Dr. Upton.
First, with regard to the experimental data that
Dr. Ellett asked about concerning cell transfor-
mation, I quite agree with Dr. Upton. I think the
use of this particular end point as indicative of
eveii any ultimate effect in producing human
cancer still has to be validated. As a matter of
fact, attempts to carry out the same kind ofstudy
by Elkind's group at Argonne did not give the
same result. It gave a lower effect of protracted
doses. So here we have a conflict that is going to
have to be resolved. But I think the important
point here isn't so much whether dose rate affects
cell systems this way or that, as it is what evi-
dence do we have in man that dose protraction is
producing less or more effect in cancer production
in man?
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We do have some data, and I think we should
not lose sight ofthis fact. For the data on breast
cancer that I showed, you will recall that in the
fluoroscopy study in Massachusetts, exposure was
to a series of repeated small doses of X-rays, on
the order of1.5 rads each time. Yet it gave exactly
the same dose-response slope as for the Nagasaki
women, who got all ofthe radiation exposure to -y-
rays at once, and also for the mastitis patients
who received relatively high doses, either in sin-
gle doses up to three or four treatments. So there
is some indication that dose protraction of low-
LET radiation in these cases did not really
change the cancer risk in man. But there are
many steps in the cancer production process that
Dr. Upton referred to, and which can undoubtedly
change some ofthe way in which a cell transfor-
mation eventually makes it through to become a
cancer. Thus we should be cautious about draw-
ing final conclusions.
Another point that I would like to emphasize
has to do with the shape of the dose-response
curve for cancer induction. Dr. Ellett implied that
you can drive a truck through any of these data
points and therefore why pick one mathematical
form over another? Well, despite the machina-
tions of the BEIR III report-which incidentally
now I think is obsolete because ofthe new Japa-
nese dosimetry-the fact ofthe matter is that the
data are really remarkably consistent. This state-
ment is quite contrary to the common refrain,
according to which people say that the data are so
uncertain you don't know what the cancer risk
really is. With the new dose calculations that I
discussed in my presentation, the Nagasaki (no-
neutron) bomb produced exactly the same dose-
response slope, going down to low doses, as the
composite of all of the world's studies on radia-
tion-induced cancers, when put together organ by
organ and added up. In other words, in the case of
theJapanese we could talk about total cancer risk
because that was one single exposure to the whole
body. For all ofthe other studies, about 50 in all,
we have only partial body radiation as the basis
of increased cancer risk. But if you take each
individual site which has an increased risk of
cancer, and you add them all up, nevertheless on
the linear hypothesis they come out right to-
gether with the Japanese (Nagasaki) results.
This I find to be a remarkable concordance-
strong set of epidemiologic evidence suggesting
that we are very close to being on the right track
by using the linear hypothesis. Because if we
weren't, we should get very disparate results
from these different studies.
The evidence on which we can base the appro-
priate dose-response curve that should be applied
to radiogenic human cancer is I think reasonably
strong, and it is getting stronger. I understand
from Dr. Beebe that the new tumor registry data
are now out for Japan. They are a follow-up
through 1978, and the linear dose-response curve
is holding even better now than it did in the 1970
follow-up that I showed. Furthermore, we can
now put the two cities together, so we are proba-
bly at the point where we can begin to see a
significant excess cancer effect at 10 rads in the
Japanese, which I think is remarkable, too. Fi-
nally, with regard to the dose-response curve in
animal studies, as distinct from human data, we
heard discussion this morning ofthe importance
ofthe cancer-promoting effect. I submit that until
protocols for animal cancer studies routinely in-
clude some kind of promoter to go along with a
putative initiator, I don't think the dose-response
data in animal populations means very much
compared to human populations. We apparently
have promoters including viruses quite widely
distributed, and therefore changes in cancer risk
are affected mainly by exposure to an initiator. In
studies in Sweden, England, the United States,
Israel, Japan, everywhere, all different popula-
tions with different cancer rates, remarkably we
get about the same cancer effect of radiation per
unitdose in all these populations. This agreement
suggests that what radiation is doing is initiating
cells; the population has enough promoters nor-
mally present that that step is not crucial, and
therefore the dose-response curve is the same for
all these different populations.
DR. WALD (Univ. ofPittsburgh): Before we leave
the subject, which is obviously of great impor-
tance, the dosimetry in Hiroshima and Nagasaki,
it would be useful if somebody would provide a
reference so some of us who aren't on the grape-
vine could find it.
DR. UPrON (Univ. ofPittsburgh): I haven't said
anything about this, and I would like a chance to
comment. To my knowledge, there is no published
information as yet from the Lawrence Livermore
National Laboratory. There is a briefing docu-
ment which contains some tables and a small
amount oftext, which summarizes the argument
that Dr. Radford referred to. Also I understand
that a paper has been submitted as a brief note,
for publication in Health Physics. However, I am
not aware that it has been accepted for publica-
tion. I think those ofyou who want to receive this
information can obtain it by writing to Dr. W. E.
Loewe of the Lawrence Livermore National La-
boratory.
Now, I have done the same sort ofreplotting of
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the tumor incidence data that Dr. Radford showed
us, and I get the same results he does. But one
paradox remains. That relates to the data for
chromosome aberrations, which Dr. Awa has pub-
lished and for which I showed a graph from his
report.
I would be much happier with the new dosime-
try if the chromosome data for the two cities
superimposed nicely. They do not. The new dosim-
etry brings the curves more nearly together than
they were before, but there is still a substantial
separation. For me, the chromosome information
ought to be more reliable in terms of confidence
intervals than the tumor data. So, there is still, I
think, some element of uncertainty about just
where the dose calculations will turn out.
I think this underscores another of Dr. Ellett's
points. The information we have, although it is
far better than most information we have on
exposures to chemicals, still admits ofsubstantial
uncertainties.
DR. RADFORD: Dr. Loewe did send me a preprint
ofhis paper in Health Physics. With regard to the
chromosomal aberration data, the Livermore
group has found exactly the same point that Dr.
Upton refers to, namely, that the difference be-
tween the two cities is not eliminated by the
change in dosimetry, and they, therefore, con-
clude that the small but still remaining neutron
fraction may have been more critical in producing
chromosomal aberrations. This does no violence
to any theoretical work in the past, which has
indicated that chromosomal aberrations are two-
break events, and they are much more likely to be
produced by high density ionization than from
low-LET radiation.
So I don't find this observation disturbing, espe-
cially since we haven't been able to associate any
disease with chromosomal aberrations, except
possibly myeloid leukemia, but even then it is a
question of whether the chromosome aberration
observed is radiation induced.
DR. ELLErT. The new Japanese data we have
now is based on a new spectrum (calculated at Los
Alamos) of the initial neutrons from the two
bombs. Then this spectrum was put in new trans-
port codes to get the dose in air at various dis-
tances from where the bomb exploded. There are
several problems with this approach. The calcula-
tion of the original neutron spectrum is not cor-
rect. We know this because it is a one-dimen-
sional treatment of neutron transport inside the
bomb, that is, a spherical bomb configuration.
Work is underway at Los Alamos and Livermore
now to do this calculation in two dimensions,
which corresponds more nearly to the true cylin-
drical shape ofthe Hiroshima bomb. When you go
to two dimensions you are going to get differ-
ences.
For another thing, what we don't know is how
the dose to individuals will change with the new
dosimetry. It may be that some people in one dose
category will slide into another dose category, so
we can't assume thatthe dose-response curves are
going to be the same when we re-evaluate the
doses in the whole population. There are two
other factors to be considered here. One is the
effect of shielding. The old neutron doses (T65)
have been calculated on one basis, both the num-
ber ofneutrons and their energies. Both ofthese
factors have changed with the new spectra. More-
over, we know the T65 gamma doses in Hiro-
shima are wrong. These have not been recalcu-
lated. The new gamma doses can go up or down,
depending on how close people were to the bomb.
At least two more years' work in dosimetry is
required on this before we can assign doses and
the correct dose intervals once these data is avail-
able.
DR. WALD: So in effect you are saying the same
thing about dosimetry in Hiroshima and Naga-
saki that was said about Hall's work on the trans-
formation: Wait and see.
DR. RADFORD: I talked to Dr. Loewe at some
length about what effect a lot of these variables
would have, and they are not going to produce
major changes. I quite agree with Dr. Ellett that
the fine details ofthe dosimetry still will have to
be worked out. But I find it a bit disturbing that
at least seven months after the Oak Ridge data
were challenged, there has been no response by
the Oak Ridge group that I am able to find in
writing anywhere. I think it is distressing that
this group, which has been the fountainhead of
knowledge in this subject for so long, is so
strangely silent. I don't think we should wait
around for the bureaucratic machinery to grind
and grind until we get all of these pieces put
together again. It is far too important to under-
stand what these effects are on the Japanese
survivors. I think it is incumbent on Government
agencies funding this research to see that it pro-
ceeds more quickly than just simply waiting for
this or that piece ofnew information to be refined
to the third decimal place.
DR. WALD: But you would allow for scientific
publication and evaluation by the scientific com-
munity?
DR. RADFORD: Oh, absolutely. That is what I
have been waiting for from the Oak Ridge group.
It is a fact that ifyou go back and try to find out
the basis for the T65 doses in detail, it is not
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possible because it never was published as such.
The only report is the one in Health Physics in
1966 which gives air doses only. I have discussed
this with several people who are knowledgeable
in this field, and they agree that the full exposi-
tion is not published in the open literature.
DR. WALD: I don't want to pursue this but I am
not sure what they would respond to since the
Livermore material isn't published.
DR. RADFORD: They were made aware of it in
August, 1980.
DR. DAVID V. BATES (University ofBritish Co-
lumbia): I amchanging the subjectfrom whatyou
have been discussing, and back to Dr. Radford's
observations on radon daughters. As he knows, I
have just finished being chairman of the Royal
Commission ofinquiry into uranium mining and
I have had an education in relation to that prob-
lem. As a comment, when people tell me they
know more about the carcinogenicity ofradiation
than any other human carcinogen, I think that
possibly is not true in relation to inhaled alpha
radiation, for which there are extremely few defi-
nite data, some contradictory.
Now, I wanted to ask Dr. Radford about the
smoking and radon daughter interaction that he
referred to. Does he agree thatthe datataken as a
whole show the lung cancers appear earlier in
smokers exposed to alpha radiation, even though
the eventual risk-if you follow your population
aslong asyouhave the Swedish workers-may be
the same? Would he agree with that and if he
agrees with that what does that tell us about
mechanisms?
And a second one, which is equally important,
in terms of protecting the uranium miner in
terms of his risk, do you believe you should add
some component of gamma and possibly routine
X-ray exposure to the calculated working level
months, annual or lifetime dose, in terms ofpro-
tective strategy? As you know, the French do
that; Americans do not do it. The Canadians, I
think are about to do it.
DR. RADFORD: In answer to your first question,
it appears that from the relatively scanty data
that we have on the issue oflatent period to onset
of cancer in smokers compared to nonsmokers
among miners, that the difference in the mean
latent period to onset between smokers and non-
smokers is a function ofdose rate. In other words,
at a high dose rate there is a fairly significant
difference, probably on the order of 15 years,
between the time to cancer in smokers compared
to nonsmokers. As the dose rate decreases, that
difference seems to disappear. It is still shorter for
the smokers, but it is much less different. Now, I
have developed a biological model which will ex-
plainthis, which I will state very quickly. It is my
view that, at high dose rates, the rate-limiting
step is the probability ofpromotion, because you
accumulate dose fast enough so that you have a
substantial population cells already initiated.
The cancers will develop then as a function of
exposure to promoters. In that case, smoking
makes a difference. As the dose rate decreases,
the rate-limiting step is the accumulation ofprob-
ability of initiation, and in this case the promo-
tion step is less important because it is present all
the time, perhaps because of intercurrent viral
infections orwhatever, and the promoters in ciga-
rette smoke play a lesser role.
With regard to the gamma dose issue, I quite
agree that it should be included, because the
gamma dose in a number of these mines is far
from negligible, a rad a year easily, possibly two.
That is whole body exposure, and thus other can-
cers besides lung cancer are now at risk. So I
think gamma exposures should be included. I
should also point out that one of the characteris-
tics of the Swedish iron mines we studied was
that the gamma doses were extremely low.
DR. JULIAN ANDELMAN (Univ. of Pittsburgh):
We heard some discussion about deciding on the
acceptability of risk, and unless I misunderstood
him, I think Dr. Radford indicated that he consid-
ered the likely consequences ofthis proposed level
ofradiation exposure to workers was to him unac-
ceptable. I would like to know what his criterion
for acceptability was.
DR. RADFORD: What I have tried to do is to put
it in scientific terms, but in some sort of context
that could be understood by a worker. It does no
good to say that the risk is 20 per 106 person years
per working level month or something. That is
not going to help the average person. What you
have to say is that ifyou get this amount ofdose,
this is what your cancer risk is likely to be plus
genetic risks and other effects. So I did that. Now,
I have reached an opinion as to what I think I
would accept or what I would consider reasonable
for a child of mine or a friend to accept. That is
one vote. It is no better necessarily than your
opinion as to whether it is acceptable, or the
opinion of anyone else in this room. I am not
saying that because I am a scientist and know a
lot about this subject that my opinion should be
the basis on which society should decide whether
the risk is acceptable or not. Quite the contrary,
as I have already indicated. I don'tthink scientific
bodies, such as the International Commission on
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Radiological Protection, should be making recom-
mendations as to what the acceptable risk should
be.
I said a 1 in 30 added risk of cancer for men
wouldbe an acceptable risk. Well, as a nonsmoker
I have 2 chances in 10 of getting cancer in my
lifetime without any radiation exposure. Now if, I
add 1 chance in 30 to that risk, I would say, if I
have a goodjob and it is paying me well, I'll take
that small risk. But someone else in the room
might say that, 1 in 30 is too much and won't
accept it. For women, a 1 in 10 risk, as added to a
3 in 10 risk or a 30% increased risk in cancer, I
would say that is not acceptable. IfI had a daugh-
ter who was going to work in that industry and
that was the kind ofrisk she was going to have to
accept in order to take thatjob, I would say don't
take it. But that is a personal thing. These are
ethical, political, social issues, not scientific.
LOWELLSIEVER(PacificNorthwestLaboratory):
I would like to address a question to Dr. Dennis-
ton. I look forward to your paper with Dr. Crow
appearing in Science. My question is: Genetic
risk-are human studies possible?
DR. DENNISTON: Touche. Let me sidestep that
and answer it this way. Are they necessary? I
alluded to this before, and let me do it again, to
see ifwe can get some controversy. My own feel-
ing is that radiation standards andperhaps chem-
ical standards as well should be based on the
measured risks of carcinogenesis, not on genetic
risks. I say that for two reasons. Despite all ofthe
controversy about whether we have good dose
levels in the Japanese data or not, from a genetic
standpoint it doesn't make much difference. We
don't have any germinal genetic effect in those
data, anyway.
My feeling is this. At least the people studying
cancer have empirical data relating exposure to
human effects. The geneticists don't have such
data. I think we are on much better grounds to
regulate on the basis of protecting the human
population from cancer and hoping that that will
effectively protect us from genetic effects than to
regulate on the basis of protecting a mouse from
genetic effects and hoping that will protect the
human population from cancer. So that would be
the first reason. The second reason is simply this
matter of discounting, because so many of the
genetic effects won't take effect for many genera-
tions in the future. I realize that for some people
it is a moral issue, but I think in practice we do
discount future generations.
I think any extrapolation beyond a few genera-
tions is so uncertain and probably so meaning-
less-and here I am not speaking for geneticists
in general-that I find the data for carcinogenesis
much more relevant to the problem ofregulation
than any ofthe data I have seen ongenetic effects.
So in a sense I am sidestepping your question on
the grounds that human studies are less neces-
sary and less relevant.
DR. UPrON: I certainly don't want to pose as
knowledgeable in genetics, but I personally have
thought that the genetic studies at Hiroshima
and Nagasaki were extremely important, not be-
cause they have given us quantitative measures
of the mutation rate or the increase in mutation
rate attributable to radiation but because they
have helped us arrive at some ballpark estimate
of upper limits of risk. I have heard Jim Neel
stress that the data coming out of those studies
lead him to feel confident that the mutation rate
doubling dose for the human population is proba-
bly in excess of 50 rads, maybe as high as 150
rads. And that is comforting. It would suggest
that the human is not inordinately more radio-
sensitive, maybe even less radiosensitive, than
the mouse. Without making those observations,
one wouldn't have had any basis on which to
compare species.
It is disappointing that we do not have precise
quantitative information and can pinpoint the
mutation rate. One of the proposals Neel has
made is to use improved technology, which makes
itpossible now to identify thousands ofindividual
proteins in cells and in blood as indices of muta-
tions, to reassess the frequency of mutations.
Each year, with recombinant DNA techniques
and gene sequencing techniques, it will become
increasingly possible to study the human genome
in detail. The question then is whether one ought
to extend the genetics studies for another 10
years and exploit the new techniques, with the
expectation that it might then be possible to
measure mutation rates in man. I daresay the A-
bomb survivor population will give us our only
such opportunity in the foreseeable future. I hope
we will not have another massive irradiation
situation ofany kind, from a bomb or a reactor or
whatever. I think the question is whether we
should exploit the Japanese experience, and I
would be interested in Dr. Denniston's comments.
DR. DENNISTON (Univ. of Wisconsin): I don't
disagree at all with what you have said. The
question in my mind was which set ofdata do we
extrapolate down from. It seems to me that at the
moment we are better off extrapolating down
from the carcinogenic data than from the genetic
data, which is based on other species primarily.
That is really my point here.
DR. RADFORD: I am somewhat in agreement
56DISCUSSION: SESSION II
with Dr. Denniston on this issue. I think the only
thing that might be useful in a regulatory sense
in considering genetic risk is that it ought to
provide a little more caution. In other words, let's
not overexpose people ifwe can possibly avoid it,
whatever one's concept ofoverexposure is. I think
that is the theme that any regulatory body would
want to adopt. Nevertheless, I am in agreement
with Dr. Denniston if you are going to put any
kind of numerical limit for radiation exposure,
thatyou should use the cancer dataprimarily and
not the genetic data.
DR. WALD: I think Dr. Upton has perhaps inad-
vertently introduced a concept which I hadn't
heard yet today in our discussion ofepidemiologic
studies of populations exposed to low doses, and
that is the possible value of a negative result
which gives us an upper limit ofrisk. In consider-
ing genetic studies in Hiroshima and Nagasaki,
there may be some value in these terms, and
perhaps there will be discussion about the value
ofsuch studies for somatic end points. Epidemio-
logic studies are always very hard to initiate
when one has exposure levels where common
sense tells you you won't find anything.
DR. UPTON: In this connection, I would like to
make one more remark, which to me is very
important, and that is to mention the revolution
in attitudes that has occurred in my lifetime.
When I began to work in radiation pathology,
nearly 30 years ago, one wouldn't have dreamed
then that carcinogenic effects would be a major
public health concern in the low dose range. Ge-
neticists, on the other hand, were concerned then
about the possibility oftransmitting untold harm
to future generations, which might imperil the
future ofthe species, by inadvertently underesti-
mating the genetic risks of low dose radiation. I
think the experience of30 years has helped us to
see that we have in carcinogenic effects a sensi-
tive measure, or a reasonably sensitive measure,
ofharm to humans at low doses. We hadn't seen
harm to humans in genetic effects we can
measure as yet. So we are prepared today to take
a radically different stance than we took 30 years
ago, and to use carcinogenic effects as a standard-
setting end point. I don't contend that this is a
wrong attitude, given what we know today, but it
represents a radical change in point ofview.
DR. PETER INFANTE (OSHA): I wonder if any of
you would care to comment on the extrapolation
of the data from Hiroshima and Nagasaki, in
terms ofgenetic risk, in view ofthe type ofexpo-
sure that occurred there. In that case there was
one exposure at one time. Often we are concerned
about chemical mutagens where there is daily
exposure to low doses. Would anyone care to com-
ment on the appropriateness of extrapolating
from one situation to the other?
DR. DENNISTON: I am not quite clear. The Hiro-
shima and Nagasaki data for genetic risk shows
no effect, so there is nothing to extrapolate from,
except, as Dr. Upton pointed out, it gives us an
upper bound on the likely effect.
DR. INFANTE: I am asking this question because
the general question was raised: Are human stud-
ies possible in terms of genetic risk? Aside from
how this risk or effect is manifested, doesn't one
also have to look at what stage in the spermato-
genic cycle the chemical may have some effect?
Could there not be an effect on fertilization at,
say, one stage during spermatogenesis, but after
those sperm were shed, there no longer will be
that effect? These are some of the concerns I
would have, because there could be a situation in
the occupational setting where workers are ex-
posed every day, whereas in irradiation, to use
the Japanese model, people were exposed once. I
am concerned about the appropriateness ofmodel
in terms of one-time exposure versus long-term
low level exposures.
DR. DENNISTON: One of the problems here is
that, in testing chemicals, we can't use the mouse
as a model. They are expensive experiments and
we are still in doubt as to whether we can extrap-
olate directly from the mouse to man, because of
some differences in the reproductive cycles and so
on.
DR. RADFORD: I think the question is whether,
for example with a chemical agent, spreading the
dose over time would inevitably hit all stages of
the spermatogenic cycle equally, whereas for rea-
sons that are not clear to me, Peter, you consider
that a single shot of radiation dose might some-
how miss some critical stages. Is that basically
what your question is?
DR. INFANTE: I really don't know the data on
radiation in terms ofwhat stage ofthe spermato-
genic cycle it may hit. Does it hit stem cells or
would it hit spermatocytes? Where does radiation
have its effect during the cycle of spermatogene-
sis?
DR. UPTON: If one gives a single exposure, as
was the situation in Hiroshima and Nagasaki,
then you hit all germ cells in essentially all
stages. You have a certain percentage ofall germ
cell stages in all stages ofcycle. Ifonly a particu-
lar stage happens tobe sensitive, as might well be
the case with chemicals, you can postulate that a
chronic exposure would have a greater effect be-
cause more of the cells would go through that
sensitive stage and experience damage.
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With radiation, the cells which accumulate
dose over a long period oftime are the spermata-
gonia in the testis and the oocytes in the ovary. In
these two germ cell stages, protracted irradiation
is less mutagenic than acute exposure. We postu-
late thatthe explanation for this lies inthe distri-
bution of ionization events, or microdosimetry.
We are not putting enough energy into sensitive
sites within the cells at any one time when we
spread the dose out in time. We do less than
sufficient damage to the geneome each time a
radiation traversal occurs.
With chemicals we might be dealing with a
very different situation. The covalent binding of
genotoxic substances to DNA given on chronic
exposure could, in fact, hypothetically cause
greater cumulative genetic damage. So I am not
at all clear that we can make a flat-footed and
simplistic extrapolation from the radiation story
to predict what will happen with chemicals. As
you know, Russell and his colleagues at Oak
Ridge have begun to look at chemicals ofvarious
kinds. In general, in the mouse system they have
used, they have seen surprisingly little evidence
of mutagenicity. The chemicals seem less muta-
genic than radiation for the same cytotoxicity.
But a striking exception, I think, is MNU (methyl-
nitrosourea), which was found to be extraordi-
narily mutagenic.
I think we still have much to learn about the
sensitivity of different germ cell stages to differ-
ent kinds of chemicals. Our ability to predict
structure-function relationships for mutagenesis
in male and female gonads is very primitive to-
day and is a major area ofresearch need.
DR. WALD: At the basic mechanism level there
are also differences, as evidenced by the produc-
tion of sister chromatid exchanges by chemicals
as distinguished from radiation effects which are
primarily breakage phenomena ofwhole chromo-
some.
I did want to make one comment as a practi-
tioner in the field of radiation protection. The
existence of an exposure limit, whether it is the
proposed EPA limit or any other, does not neces-
sarily mean your daughter or my son will get
exposures up to that limit. We found thatwith the
present limit, and I think it would be so with the
proposed limit as well, one has to be cautious
about extrapolating population risks to a limit
number which will very unlikely be achieved by
any but a very small percentage of the popula-
tion.
DR. ELLErr The EPA has not proposed 100 rem
as a lifetime limit. What they have proposed is an
objective for the planning ofexposures to workers
over longperiods oftime, that is, the lifetime dose
should be designed to be below a hundred rem.
But it would not be a legal limit like the one we
have nowwhich amountsto a lifetime limit of235
rem. There is some feelingthat istoo high. We are
suggesting that people should arrange radiation
protection suchthatthe lifetime exposure will not
exceed ahundredrem. But it is not a limit, it is an
objective; there is a lot ofdifference.
DR. RADFORD: I would just like to say a word
aboutthese lifetime exposure limits forworkers. I
agree with both points made by Niel Wald and
also by Bill Ellett, that these are guidelines not
intendedtobe exceeded, andonly a small percent-
age ofthe work force would reach them. That still
doesn't mean that it isn't an important objective
because the purpose here is to protect the individ-
ual worker. It is clear among people who know
how these doses are accumulated within nuclear
facilities or industrial operations using radiation
in the nonnuclear industry, only a small percent-
age ofthe work force gets most ofthe dose. Usu-
ally in nuclear facilities, it is the maintenance
workers and health physicists. Those are the
workers we are really trying to protect, it seems
to me.
Second, at a hearing where I gave some testi-
mony last month, the question was asked by a
panelist: what ifa worker gets up to 100 rem and
he had reached retirement, but he wants to go
and do some other kind ofjob which will give him
an additional radiation exposure; shouldn't he
have the option? It gets down to a question of
choice by the individual. I am not a strong advo-
cate of these rigid numbers. I think ultimately
the decision is between the worker and his man-
agement. The worker can say, well, I already
have 100 rads so I have a certain cancer risk, but
I don't mind ifI get a little more. He should have
that right.
LEwIs ROWE (Houston, Texas): Is there any in-
formation concerning the exposure to radiation
and the resistance or susceptibility to infectious
disease?
DR. UPrON: There is no question that one can
cripple the immune system with large doses. It
was discovered that one could rescue lethally
irradiated rats or mice by transplanting foreign
bone marrow cells into those animals, and that
doses which would kill every mouse-such as a
thousand rads delivered acutely in whole-body
irradiation-would be non-lethal if one simply
put in a few nonirradiated bone marrow cells
after exposure. Furthermore, the cells could come
from rats, and the mouse wouldn't reject them
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intensive high dose irradiation knocks out the
immune system. That is clear.
What isn't clear is the effect of small doses
spread out over a long period oftime. There is a
paradoxical result in some experiments; namely,
that rats and mice which do not enjoy optimal
longevity because they are housed in rather un-
sanitary environments tend to show an increase
in mean survival time if they are given a little
radiation every day. When the observation was
first noted and reproduced, people siezed on it and
said that a little radiation is good for you, we
thought so all along. Well, it turns out that the
mean survival of those irradiated animals isn't
equal to the mean survival of animals that are
maintained in good environments. But the obser-
vation has been interpreted to suggest that small
doses ofradiation may in fact improve resistance
to intercurrent infection.
We simply don't know whether in the human
population such as ours, living in a relatively
favorable environment, a little radiation would in
fact decrease the susceptibility of some individ-
uals to infection. We know that it damages chro-
mosomes. We know that it increases the fre-
quency of abnormal lymphocytes. And there is
some suggestion that it leads to an increased
frequency of monoclonal gammopathies, that is,
immunocytes which produce faulty immune glo-
bulin. So I think there is no reason to suggestthat
the animal data should make us want to go out
and prescribe a little radiation.
I am inclined to think that the bulk of the
evidence argues that a little radiation is deleteri-
ous, but at natural background levels or levels
associated with maximum permissible occupa-
tional exposures, I doubt that we can now
measure effects on the immune response.
DR. WALD: Dr. Upton, would you include any
effect of radiation on capability for immunosur-
veillance, that is, a reduction in the ability to
recognize abnormal cells and eliminate them?
DR. UPTON: Well, certainly in the high dose
range immunological surveillance will be im-
paired. We are talking probably ofdoses in excess
of 100 rads given over short periods of time.
Whether 100 rads accumulated over a working
lifetime would have any effects on the immune
system is a moot question. I don't know of any
existing evidence that will settle that point.
DR. YVES C.E. ALARIE (Univ. ofPittsburgh): I
have heard this issue discussed all day and some-
how it is bothering me. Several times we have
said, well, ifwe give the worker an adequate risk-
benefit analysis, thatworkerhas therightthento
takethatjob andexposehimselforherself. This is
to me the equivalent of saying that we do build
bridges, and we tell people don't jump off the
bridge. But we'll give you a risk-benefit analysis,
and then ifyou want to jump offthe bridge, you
can go ahead and do it. Somehow there is some-
thing wrong here.
DR. RADFORD: I guess that comment is in re-
sponse to my remark that ifa worker had already
received some radiation dose he oughtto have the
right to continue exposure in perhaps other sur-
roundings. It does come down to the issue dis-
cussed earlier about an acceptability of risk. I
grantthe difference in risk that is goingto lead to
sure demise in an individual, like jumping off a
bridge, compared to these kinds of risks from
radiation, which are subtle and long-standing
and are probabilistic kinds ofthings.
I think intuitively most ofus do accept the fact
that we may be running certain risks in certain
activities, including things like motorcycle riding
or skiing, but we accept those risks. But the point
is, I don't think we really have a good handle on
how to make these comparisons. Nevertheless, I
think making a lot ofthe difference between 100
rads and 105 rads is a bit ridiculous.
DR. WALD: I suppose what is really being said,
and we can say this in Pennsylvania particularly,
isthatthere are people who are willingtowork in
coal mines because the cost-benefit for them
comes out on the benefit side. We knowthere is an
increased risk but nevertheless, we allow them to
proceed.
DR. ALARIE: I am talking of the philosophy
being expressed today ofsaying yes, we will give
you a risk-benefit ratio, and then saying the per-
son has a right to interpret it. Does one have a
right tojump offthe bridge, too?
DR. ELLETP. What we essentially have today is
a two-tier system. First, responsibility is on that
person controlling the source, or the employer,
and second on the person who is receiving the
dose, which is the worker. In radiation protection,
the workers' doses are limited by two sets of
regulations. One that gives them a maximum
annual dose; one that gives them a maximum
lifetime dose. Essentially we say ifyou get above
the lifetime dose, you are unemployable in radia-
tion work. It doesn't mean you are unemployable
but it means you have to change the kind ofwork
you do. Frankly, I don't know of any case where
this has happened, because they don't count acci-
dental exposures, so as near as we can find out no
worker is even close to 100 rem. In a sense, the
100 rem lifetime dose isn't too pertinent a limit.
I don't see though where you can differentiate
between a man who takes a radiationjob to earn
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a living and somebody who drives a steel truck or
somebody who goes down in a coal mine. People
do not take these risks voluntarily and they
shouldn't be looked at in that light. I think one of
the problems I have when I go to meetings where
we do risk analysis, those present have essen-
tially middle-class biases. But this is a real world
where many people are not in the middle class. A
man who works in a steel plant knows whichjobs
are dangerous in the shop and he knows that as
he develops seniority he can be transferred from a
dangerousjob to a less dangerousjob. The people
who get hurt in industrial plants are younger
workers, one, because they are more inexpe-
rienced and careless and, two, because they are
put on the worstjobs. And that is the society we
live in and I think we might as well face it.
DR. RADFORD: I would like to second the point
Billjust made. I think it is unfortunate, Neil, that
you mentioned coal miners. I don't think the risks
of coal mining have ever been explained ade-
quately to the workers. We now have pretty good
epidemiologic data that enables us to say what
the probability of a fatal accident would be per
unit mined per year or whatever, or what proba-
bility there would be for a nonfatal accident, or
the probability ofstomach cancer, ofwhich there
seems to be an excess. These risks have never
been explained to the coal miners. So to say that
they have accepted on a cost-benefit basis that is
to their benefit to go down in the mines, I dis-
agree. Furthermore, in Britain, the risks of coal
mining have been made sufficiently manifest,
simply by the continuing toll on the miners, that
the companies can't get enough miners to go in to
the mines. We have a coal strike going on right
now. I have a feeling that risk perception is one of
the strong reasons why the rank and file no
longer follow the union leadership.
DR. WALD: I do thinkthey are aware ofthe risks
even without epidemiological data.
DR. CHARLESPOOLE(EPA): I think the program
committee should be congratulated for putting
Dr. Kasperson on the program today. The discus-
sion his talk aroused really illustrates the schizo-
phrenia that I think all ofus should feel when, if
we came into epidemiology orbiostatistics expect-
ing to be scientists, we also realize we are public
health workers; or, if we came into the field ex-
pecting to be public health workers and we recog-
nize we have to be scientists as well. But I would
like to make a point on another topic.
In clarification, I think, for Dr. Bates' question
which I think Dr. Radford responded to concern-
ing the time to occurrence among people doubly
exposed to radon daughters and smoking. I think
Morrison and Guess and Hoel independently
showed that there is an inherent mathematical-
and I emphasize the word mathematical-rela-
tionship between increased risk and time to oc-
currence. If the annual attributal risk goes up,
the average time to occurrence goes down. So I
don't think we really have to go to fancy biologi-
cal explanations for that phenomenon.
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